Thyrocare Technologies Shares Hit Eight-Month High After Rise In Q4 Net Profit

Shares of Thyrocare Technolgies Ltd. hit an eight-month high on Thursday after its profit rose 22% in the fourth quarter of financial year 2025.

The healthcare diagnostics company recorded a consolidated net profit of Rs 21.7 crore for the quarter ended March, compared to Rs 17.8 crore in the same quarter of the previous fiscal.

Revenue increased by 21.3% year-on-year for the three months ended March, reaching Rs 187 crore. Operating income, or earnings before interest, taxes, depreciation, and amortisation, rose 70.7% year-on-year to Rs 57.7 crore. The Ebitda margin expanded to 30.8% from 21.9% reported in the same period last year.

The board also recommended a final dividend of Rs 21 per share.

Pathalogy and radiology segments saw a growth of 23% and 7% year-on-year, respectively. While the revenue from franchises rose by 22% year-on-year, partnership revenue grew by 24% year-on-year.

The company's active franchises rose 16% year-on-year to 11,000 and patient count rose 11% year-on-year to 16.7 million. The laboratory chain has conducted 167.9 million tests, 14% higher from the tests conducted in the same quarter of the previous fiscal.

Shares of Thyrocare rose as much as 18.66% intraday, the highest level since Aug. 26, 2024. They pared gains to trade 15.18% higher at Rs 886 apiece, as of 10:03 a.m., compared to a 0.24% decline in the NSE Nifty 50.

The stock has fallen 2.67% year-to-date and risen 34.53% in the last 12 months. Total traded volume so far in the day stood at 1.12 times its 30-day average. The relative strength index was at 62.

All three analysts tracking the company maintain a 'buy' rating, according to Bloomberg data. The average 12-month analysts' consensus price target implies an upside of 9.8%.